alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › lc-ms

lc-ms

3 studies tagged lc-ms, dated 2023-04-01 to 2024-08-10. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology 2024-08-10
  2. Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer's disease assessment 2024-03-25
  3. Clinical utility of an antibody-free LC-MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study 2023-04-01

Studies

3 studies carry this tag.

Date range

2023 to 2024

Top journals

  • Alzheimer's & dementia (Amsterdam, Netherlands) 1
  • Diagnostics (Basel, Switzerland) 1
  • Frontiers in neurology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Diagnostics (Basel, Switzerland) 2024-08-10 Biomarkers

    Alzheimer's disease (AD) is a progressive irreversible neurodegenerative disorder that represents a major global public health concern.

  2. Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer's disease assessment

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Frontiers in neurology 2024-03-25 Biomarkers

    High-throughput plasma Aβ42/40 LC-MS/MS assays can help identify patients with low likelihood of AD pathology, which can reduce PET evaluations, allowing for cost savings.

  3. Clinical utility of an antibody-free LC-MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2023-04-01 Biomarkers

    ABtest-MS accurately identified brain amyloid deposition in a population of CU individuals, supporting its implementation in AD secondary prevention trials to reduce recruitment time and costs.

All topic tags with their study counts